Abstract: Disclosed are sodium salts of pyrimidine derivatives, and a series of crystal forms thereof. The series of crystal forms exhibit a good druggability, such as stability, fluidity, compressibility, etc., and provide a variety of options of APIs for subsequent drug product development.

Abstract: Disclosed is the use of isothiocyanate compounds. In particular, disclosed is the use of a compound as shown by Formula (I) or a derivative as shown by Formula (II) in the manufacture of a composition or preparation for preventing and/or treating hyperlipidemia. The compound of the present invention can reduce the levels of triglycerides and low density lipoproteins in the serum of mammals (such as rats and humans), increase the level of high density lipoproteins in the serum, and reduce the level of total bilirubin in the serum of mammals (such as rats and humans).

Abstract: A frequency modulation demodulator based on fiber grating sensor array comprises: a laser, radio frequency signal source, acousto-optic modulator, delay fiber pair, Mach-Zehnder modulator, optical filter, optical amplifier, optical isolator, circulator, fiber grating sensor array, photodetector and data acquisition card. By the cooperation of delay fiber pair and the fiber grating, the reflected optical pulses of the two gratings (the front grating and the back grating) are overlapped in the time domain to form interference, and thereby achieving multi-point array interference demodulation.

Abstract: A frequency modulation demodulator based on fiber grating sensor array comprises: a laser, radio frequency signal source, acousto-optic modulator, delay fiber pair, Mach-Zehnder modulator, optical filter, optical amplifier, optical isolator, circulator, fiber grating sensor array, photodetector and data acquisition card. By the cooperation of delay fiber pair and the fiber grating, the reflected optical pulses of the two gratings (the front grating and the back grating) are overlapped in the time domain to form interference, and thereby achieving multi-point array interference demodulation.

Abstract: Disclosed is the use of isothiocyanate compounds. In particular, disclosed is the use of a compound as shown by Formula (I) or a derivative as shown by Formula (II) in the manufacture of a composition or preparation for preventing and/or treating hyperlipidemia. The compound of the present invention can reduce the levels of triglycerides and low density lipoproteins in the serum of mammals (such as rats and humans), increase the level of high density lipoproteins in the serum, and reduce the level of total bilirubin in the serum of mammals (such as rats and humans).

Abstract: The present invention relates to a combined application of isothiocyanate compounds and anti-cancer drugs, in particular to a composition, comprising: (A) a therapeutically effective amount of a first active ingredient, the first active ingredient being an isothiocyanate compound or derivative thereof; (B) a therapeutically effective amount of a second active ingredient, the second active ingredient being anti-cancer drugs effecting or influencing DNA, kinase inhibitor anti-cancer drugs or endocrine therapy hormonal anti-cancer drugs, the mass ratio of the first active ingredient and the second active ingredient being from 1:10000 to 10000:1. Also disclosed are an active ingredient composition, kit, pharmaceutical composition and uses thereof in the preparation of anti-cancer drugs. The composition, active ingredient composition and kit have excellent effect of inhibiting the growth of cancer cells.

Abstract: The present invention relates to a combined application of isothiocyanate compounds and anti-cancer drugs, in particular to a composition, comprising: (A) a therapeutically effective amount of a first active ingredient, the first active ingredient being an isothiocyanate compound or derivative thereof; (B) a therapeutically effective amount of a second active ingredient, the second active ingredient being anti-cancer drugs effecting or influencing DNA, kinase inhibitor anti-cancer drugs or endocrine therapy hormonal anti-cancer drugs, the mass ratio of the first active ingredient and the second active ingredient being from 1:10000 to 10000:1. Also disclosed are an active ingredient composition, kit, pharmaceutical composition and uses thereof in the preparation of anti-cancer drugs. The composition, active ingredient composition and kit have excellent effect of inhibiting the growth of cancer cells.